These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36641771)

  • 21. Follow-Up of Thyroid Function in Children With Neonatal Hyperthyroidism.
    Pyrżak B; Rumińska M; Witkowska-Sędek E; Kucharska A
    Front Endocrinol (Lausanne); 2022; 13():877119. PubMed ID: 35600602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 25-Hydroxyvitamin D serum level in Hashimoto's thyroiditis, but not Graves' disease is relatively deficient.
    Ke W; Sun T; Zhang Y; He L; Wu Q; Liu J; Zha B
    Endocr J; 2017 Jun; 64(6):581-587. PubMed ID: 28413173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Storm in a Patient With Alemtuzumab-Induced Graves' Disease: A Case Report.
    AlShehri S; Alajmi S; Ekhzaimy A; Aldawas S; Alalwan M
    Cureus; 2022 Apr; 14(4):e24570. PubMed ID: 35651398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Severe Graves' Hyperthyroidism in Pregnancy Following Immune Reconstitution Therapy in Multiple Sclerosis.
    Hammerstad SS; Celius EG; Husby H; Sørensen IM; Norheim IE
    J Endocr Soc; 2021 Jun; 5(6):bvab044. PubMed ID: 34017934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab-Induced Autoimmune Thyroid Dysfunction.
    Ragavan S; Elhelw O; Majeed W; Kyriacou A; Syed A
    Cureus; 2022 Mar; 14(3):e22751. PubMed ID: 35371892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.
    Muller I; Moran C; Lecumberri B; Decallonne B; Robertson N; Jones J; Dayan CM
    Eur Thyroid J; 2019 Jul; 8(4):173-185. PubMed ID: 31602359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
    Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
    Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study.
    Eichau S; López Ruiz R; Ruíz de Arcos M; Ruiz-Peña JL; Navarro G; Calleja MÁ; Moreno-Amador JL; Dotor García-Soto J
    Front Neurol; 2023; 14():1112193. PubMed ID: 36998778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
    Coles AJ; Jones JL; Vermersch P; Traboulsee A; Bass AD; Boster A; Chan A; Comi G; Fernández Ó; Giovannoni G; Kubala Havrdova E; LaGanke C; Montalban X; Oreja-Guevara C; Piehl F; Wiendl H; Ziemssen T
    Mult Scler; 2022 Apr; 28(5):842-846. PubMed ID: 34882037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
    Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
    Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.
    Dunn A; Lam A; Hidalgo L; Shapiro AMJ; Senior PA
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1141-1147. PubMed ID: 30398662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease.
    Rayman MP
    Proc Nutr Soc; 2019 Feb; 78(1):34-44. PubMed ID: 30208979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset.
    Yap SM; Dillon M; Crowley RK; McGuigan C
    Mult Scler J Exp Transl Clin; 2020; 6(2):2055217320933928. PubMed ID: 32612846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis.
    Le Moli R; Russo M; Malandrino P; Vella V; Belfiore A; Frasca F
    Hormones (Athens); 2021 Mar; 20(1):161-165. PubMed ID: 32500462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum polyamine metabolic profile in autoimmune thyroid disease patients.
    Song J; Shan Z; Mao J; Teng W
    Clin Endocrinol (Oxf); 2019 May; 90(5):727-736. PubMed ID: 30725486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases.
    Zhu Y; Portmann L; Dénéréaz N; Lemarchand-Béraud T
    Eur J Endocrinol; 1994 Oct; 131(4):359-68. PubMed ID: 7921224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.